- From Theranostics to Immunotheranostics: the Concept
-
Schaefer N, Prior JO, Schottelius M
- KMID: 2500061
- Nucl Med Mol Imaging.
- 2020 Apr;54(2):81-85.
- doi: 10.1007/s13139-020-00639-6
Immunotheranostics will be an important development in the future of nuclear medicine and medical oncology. It describes the synergy of theranostic procedures in nuclear medicine and immune oncology (IO) treatment. In... -
- CITED
-
- Close
- SHARE
-
- Close
- New Frontiers in Molecular Imaging with Superparamagnetic IronOxide Nanoparticles (SPIONs): Efficacy, Toxicity, and FutureApplications
-
Frantellizzi V, Conte M, Pontico M, Pani A, Pani R, Vincentis G
- KMID: 2500060
- Nucl Med Mol Imaging.
- 2020 Apr;54(2):65-80.
- doi: 10.1007/s13139-020-00635-w
Supermagnetic Iron Oxide Nanoparticles (SPIONs) are nanoparticles that have an iron oxide core and a functionalized shell. SPIONs have recently raised much interest in the scientific community, given their exciting potential... -
- CITED
-
- Close
- SHARE
-
- Close
- Renal Potassium Excretion Visualized on 82Rubidium PET/CT
-
Jochumsen M, Tolbod LP, Borre M, Frøkiær J, Bouchelouche K, Sörensen J
- KMID: 2500066
- Nucl Med Mol Imaging.
- 2020 Apr;54(2):120-122.
- doi: 10.1007/s13139-020-00637-8
The positron emission tomography (PET) flow tracer 82Rubidium is a known potassium analogue. During our studies of tumor blood flow in prostate cancer, we found that approximately 10% of the patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Sleep and Neuroimaging
-
Pak K, Kim J, Kim K, Kim SJ, Kim IJ
- KMID: 2500063
- Nucl Med Mol Imaging.
- 2020 Apr;54(2):98-104.
- doi: 10.1007/s13139-020-00636-9
We spend about one-third of our lives either sleeping or attempting to sleep. Therefore, the socioeconomic implications of sleep disorders may be higher than expected. However, the fundamental mechanisms and functions... -
- CITED
-
- Close
- SHARE
-
- Close
- First In-Human Medical Imaging with a PASylated 89Zr-LabeledAnti-HER2 Fab-Fragment in a Patient with Metastatic Breast Cancer
-
Richter A, Knorr K, Schlapschy M, Robu S, Morath V, Mendler C, Yen HY, Steiger K, Kiechle M, Weber W, Skerra A, Schwaiger M
- KMID: 2500065
- Nucl Med Mol Imaging.
- 2020 Apr;54(2):114-119.
- doi: 10.1007/s13139-020-00638-7
Purpose PASylation® offers the ability to systematically tune and optimize the pharmacokinetics of protein tracers for molecular imaging. Here we report the first clinical translation of a PASylated Fab fragment (89Zr∙Df-HER2-Fab-PAS200)... -
- CITED
-
- Close
- SHARE
-
- Close
- Preclinical Voxel-Based Dosimetry in Theranostics: a Review
-
Gupta A, Lee MS, Kim JH, Lee DS, Lee JS
- KMID: 2500062
- Nucl Med Mol Imaging.
- 2020 Apr;54(2):86-97.
- doi: 10.1007/s13139-020-00640-z
Due to the increasing use of preclinical targeted radionuclide therapy (TRT) studies for the development of novel theranostic agents, several studies have been performed to accurately estimate absorbed doses to mice... -
- CITED
-
- Close
- SHARE
-
- Close
- Radioactivity Reduction of 2-Deoxy-2-[18F] Fluoro-D-Glucose by Milkand Ursodeoxycholic Acid in Preclinical Study
-
Jeong HJ, Bagalkot TR, Kim HS, Han YH, Kim M, Lim ST, Sohn MH
- KMID: 2500064
- Nucl Med Mol Imaging.
- 2020 Apr;54(2):105-113.
- doi: 10.1007/s13139-020-00634-x
Purpose 2-Deoxy-2-[18F] fluoro-d-glucose positron emission tomography (18F-FDG-PET) is a less-invasive and widely used diagnostic tool for detection of malignant tumors. However, prolonged retention of 18F-FDG in the body increases radiation exposure. This... -
- CITED
-
- Close
- SHARE
-
- Close
